Article Text

PDF
Review: omalizumab reduces exacerbation and steroid use in chronic asthma

Statistics from Altmetric.com



Q In adults and children with chronic asthma, is omalizumab (a recombinant humanised monoclonal anti-IgE referred to as rhuMAb-E25, rhu-Mab, or Xolair) better than placebo for clinical outcomes?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Respirology ★★★★★★☆ Paediatrics ★★★★★★☆ Allergy & immunology ★★★★★☆☆

METHODS

Embedded ImageData sources:

Cochrane Airways Group Asthma and Wheeze trials register (up to February 2006), reference lists of relevant studies and review articles, all pharmaceutical companies producing anti-IgE formulations, 2 websites (www.fda.gov and www.clinicalstudyresults.org), meeting abstracts, and experts in the field.

Embedded ImageStudy selection and assessment:

randomised and blinded controlled trials (RCTs) in any language that included adults and children with chronic asthma and compared anti-IgE at any dose or route with placebo. 14 RCTs (n  =  3143) met the selection criteria. Quality …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.